Piramal Pharma to Buy the Remaining 26% Stake in Yapan Bio
Piramal Pharma has decided to exercise its call option for the balance 26% of vaccines and biologics CDMO Yapan Bio, lifting its holding from 74% to 100%.
Key Takeaways
- Piramal Pharma will buy the remaining 26% equity stake in Yapan Bio by exercising its call option.
- Its holding is set to rise from 74% to 100%, making Yapan Bio a wholly owned subsidiary.
- The acquisition price and the share transfer date have not been finalised yet.
- Yapan Bio is a Hyderabad-based CDMO for vaccines and biologics.
- Piramal Pharma first invested in Yapan Bio in December 2021 and raised its stake to 74% in August 2026.
Table of Contents 6 sections
Piramal Pharma will acquire the remaining 26% equity stake in Yapan Bio Private Limited, a contract development and manufacturing organisation (CDMO) for vaccines and biologics. The drugmaker told the stock exchanges on November 18, 2026 that it has decided to exercise its call option for the balance stake.
Piramal Pharma already owns 74% of Yapan Bio. Once the deal is completed, its holding is set to rise to 100%, and Yapan Bio will become a wholly owned subsidiary. The price for the stake and the date on which the shares will change hands have not been finalised yet.
Piramal Pharma's Yapan Bio buyout at a glance
| Detail | Value |
|---|---|
| Buyer | Piramal Pharma Limited |
| Target | Yapan Bio Private Limited |
| Stake being bought | Remaining 26% |
| Route | Exercise of Piramal Pharma's call option |
| Approved by | Administrative committee authorised by Piramal Pharma's board |
| Holding now | 74% |
| Holding after completion | 100% (wholly owned subsidiary) |
| Price and transfer date | Not finalised yet |
| Announced | November 18, 2026 |
How Piramal Pharma's board cleared the Yapan Bio call option
The decision was approved by an administrative committee of Piramal Pharma's board of directors, acting under powers given to it by the board. Piramal Pharma said that after exercising the call option, it is in talks with Yapan Bio's shareholders on the matters needed to complete the deal.
The exercise of the option does not mean the shares have already moved. The final terms, including the acquisition price and the effective date of the share transfer, are still to be settled.
Yapan Bio, the Hyderabad vaccines and biologics CDMO
Yapan Bio is a Hyderabad-based CDMO. It offers process development, characterisation and Phase I/II GMP manufacturing services for vaccines and biologics.
Piramal Pharma first bought a 27.78% stake in December 2021 for Rs 101.77 crore. In August 2026, it bought an additional 40.67% stake for about Rs 76 crore, taking its holding from 33.33% to 74%, and Yapan Bio changed from an associate company into a subsidiary. Yapan Bio works within Piramal Pharma Solutions, Piramal Pharma's CDMO business.
| When | What happened |
|---|---|
| December 2021 | Piramal Pharma invested Rs 101.77 crore in Yapan Bio for a 27.78% stake |
| August 2026 | Piramal Pharma bought an additional 40.67% stake for about Rs 76 crore, raising its holding from 33.33% to 74% and making Yapan Bio a subsidiary |
| November 18, 2026 | Piramal Pharma decided to exercise its call option for the remaining 26% stake |
What Piramal Pharma has said about closing the Yapan Bio deal
Piramal Pharma said it will make further disclosures once the definitive documents are signed and the transaction is completed.
Where Piramal Pharma's Yapan Bio stake stands now
Piramal Pharma holds 74% of Yapan Bio today, after starting with a 27.78% stake in December 2021. The purchase of the remaining 26% would make Yapan Bio a wholly owned subsidiary. Piramal Pharma said it is in talks with Yapan Bio's shareholders to complete the deal.
More news
Frequently Asked Questions
What is Yapan Bio?
How much of Yapan Bio is Piramal Pharma buying?
How much of Yapan Bio does Piramal Pharma own now?
How will Yapan Bio's status change after the deal?
How is Piramal Pharma acquiring the Yapan Bio stake?
Who approved Piramal Pharma's Yapan Bio deal?
What price is Piramal Pharma paying for the Yapan Bio stake?
When will the Yapan Bio shares be transferred to Piramal Pharma?
When did Piramal Pharma announce the Yapan Bio deal?
When did Piramal Pharma first invest in Yapan Bio?
How did Piramal Pharma reach a 74% stake in Yapan Bio?
What has Piramal Pharma said about the next step in the Yapan Bio deal?
More in Business
Stylam Industries to Buy a 51% Stake in Haripur Kraft Co
Stylam Industries will put up to Rs 22.44 crore into kraft paper maker Haripur Kraft Co for a 51% stake.
Aurionpro Wins About Rs 100 Crore AI Data Centre Order
Aurionpro has won an order of close to Rs 100 crore for an AI-ready data centre in Southern India.
Bharat Forge Puts About Rs 291 Crore Into Defence Arm KSSL
Bharat Forge has invested Rs 290.51 crore in its defence arm KSSL through a rights issue.
